Autosomal Recessive Cerebral Atrophy (ARCA)

Autosomal recessive cerebral atrophy means the brain slowly shrinks (loses volume) because of a genetic problem that a child inherits from both parents. Each parent carries one silent, non-working copy of a gene, and when a child receives both non-working copies, brain cells cannot grow or work normally. Over time, MRI scans show wider grooves and bigger brain fluid spaces because tissue is lost. Symptoms often start in infancy or early childhood with slow development, seizures, feeding and movement problems, learning difficulties, and sometimes problems with vision, hearing, or behavior. The exact course depends on which gene is affected. Doctors confirm the cause by combining brain MRI, EEG?, metabolic blood/urine tests, and exome/genome sequencing to pinpoint the defective gene; modern genetics is recommended early because it increases the chance of a clear diagnosis? and may open targeted options or trials. OUP Academic+2Frontiers+2

Other names

Doctors and databases may use slightly different labels for the same rare phenotype. You may see: “Autosomal-recessive cerebral atrophy,” “AR cerebral atrophy,” “progressive cerebral atrophy of infancy,” or a database code/name (e.g., Orphanet/MONDO entries) attached to the same clinical? picture described above. These refer to the same core idea: a genetic, autosomal-recessive disorder with early-onset?, progressive cerebral volume loss. Orpha+2rarediseases.info.nih.gov+2

Types

Because ARCA is a phenotypic description, clinicians often sort cases by underlying cause rather than one uniform disease. Think of ARCA as a final common pathway shared by multiple genetic diseases that damage the cerebrum? early in life. Helpful “types” (groupings) include: (1) Primary cortical neurodegenerations of infancy, (2) leukodystrophies (inherited white-matter diseases) with atrophy, (3) lysosomal storage disorders such as neuronal ceroid lipofuscinoses (NCLs), (4) mitochondrial disorders with cortical involvement, and (5) rare RNA/DNA processing disorders and related neurodevelopmental syndromes. Classifying a child into one of these buckets guides testing and prognosis?. National Organization for Rare Disorders+2Europe PMC+2

Examples of “type” buckets that can present with cerebral atrophy:

• Leukodystrophies (genetic myelin disorders) can include hypomyelination plus progressive atrophy on MRI; examples range from TUBB4A-related leukodystrophy to other genetic white-matter conditions. NCBI+1

• Neuronal ceroid lipofuscinoses (NCLs) show progressive cerebral and/or cerebellar atrophy with seizures and vision loss; MRI and EEG patterns can support the diagnosis while genetic testing confirms the subtype. PubMed Central+2ajnr.org+2

• Pontocerebellar hypoplasias (PCHs) are primarily pons/cerebellum disorders but may coexist with supratentorial (cerebral) atrophy in some subtypes; they emphasize how overlapping phenotypes can occur in genetic neurodevelopmental disease. National Organization for Rare Disorders+3NCBI+3NCBI+3

Causes

Below are cause categories and illustrative mechanisms that can lead to the ARCA picture. Each item explains “how this could shrink the cerebrum” in simple terms.

1. Primary autosomal-recessive cortical degenerations of infancy. Some rare AR genes directly affect neurons in the cortex, causing early, symmetric loss of brain volume and developmental regression. Orpha+1

2. Leukodystrophies (genetic white-matter diseases). Faulty myelin formation or maintenance leads to white-matter loss and secondary cortical atrophy over time; MRI may show hypomyelination with brain shrinking. National Organization for Rare Disorders+1

3. Lysosomal storage disorders (e.g., NCLs). When cell “recycling centers” fail, toxic material builds up in neurons, causing progressive loss of cortical volume, seizures, and vision decline. Frontiers+1

4. Mitochondrial disorders. Energy failure in brain cells promotes neurodegeneration, sometimes with cortical thinning and ventriculomegaly on MRI. jnnp.bmj.com

5. Peroxisomal disorders. Defects in peroxisome function disrupt lipid metabolism and myelin, leading to cerebral white-matter disease and atrophy. National Organization for Rare Disorders

6. Congenital? disorders of glycosylation. Abnormal protein glycosylation impairs neuronal development, causing microcephaly, hypotonia, and progressive cortical loss. National Organization for Rare Disorders

7. Defects of RNA exosome/processing complexes (e.g., EXOSC genes). RNA handling errors disturb neuron survival; some subtypes show combined brain volume loss and motor neuron involvement. NCBI

8. Tubulinopathies (e.g., TUBB4A spectrum). Cytoskeletal defects alter brain wiring and myelination; MRI can show hypomyelination with atrophy. NCBI

9. DNA repair disorders. Inability to fix DNA damage makes neurons vulnerable, eventually causing cortical atrophy and neurodevelopmental regression. jnnp.bmj.com

10. Autosomal-recessive ataxia? syndromes with cortical involvement. Although many ataxias target the cerebellum, some AR forms include supratentorial atrophy and developmental issues. NCBI

11. Neuroaxonal dystrophy/PLA2G6-related disorders. Axonal spheroids and neurodegeneration can reduce brain volume over time, sometimes with early childhood onset. jnnp.bmj.com

12. Inborn errors of metabolism (non-lysosomal). Problems in amino acid, organic acid, or energy pathways can poison or starve neurons, producing progressive atrophy. National Organization for Rare Disorders

13. Channelopathies with developmental encephalopathy. Severe? epileptic encephalopathies (genetic) can drive cerebral and cerebellar atrophy on serial imaging. Seizure Journal

14. Thiamine transport/metabolism defects. Vitamin-dependent pathways are essential for neuronal energy; untreated defects can lead to cortical injury and atrophy. National Organization for Rare Disorders

15. Cyclic nucleotide/second-messenger pathway defects. Disrupted signaling during brain development can impair synapse formation and survival, shrinking cortex over time. jnnp.bmj.com

16. Fatty-acid metabolism defects. Abnormal lipid handling damages myelin and neurons, leading to white-matter loss and cortical thinning. National Organization for Rare Disorders

17. Autophagy pathway defects. Impaired cellular “cleanup” leads to toxic accumulation in neurons, a mechanism shared with some NCLs. Frontiers

18. Transcription/translation factor defects. When master regulators of brain development are mutated, cortical structure and maintenance fail, producing early atrophy. jnnp.bmj.com

19. Glycosphingolipid disorders. Abnormal membrane lipids injure white matter and cortical neurons, causing progressive volume loss. National Organization for Rare Disorders

20. Undiagnosed genetic etiologies (yet to be found). Even with modern panels and exome/genome sequencing, a fraction of children remain “unsolved,” but the pattern still signals a genetic cause. jnnp.bmj.com

Symptoms

1. Developmental regression. A child who had learned skills (eye contact, rolling, feeding, words) gradually loses them; this is a hallmark of progressive neurodegeneration. rarediseases.info.nih.gov

2. Acquired microcephaly. The head growth rate falls off, reflecting loss of brain volume after birth. rarediseases.info.nih.gov

3. Feeding difficulty. Weakness?, tone problems, and poor coordination lead to poor suck, choking, or the need for tube feeding. disorders.eyes.arizona.edu

4. Irritability and excessive startle. Overactive startle and agitation often accompany early cortical injury and brain hyperexcitability. rarediseases.info.nih.gov

5. Spasticity or mixed tone. Trunk may be hypotonic (floppy) while arms/legs become stiff or scissored, reflecting cortical motor pathway damage. rarediseases.info.nih.gov

6. Abnormal movements (akathisia, dystonia). Involuntary restlessness or twisting movements can occur as pathways degenerate. rarediseases.info.nih.gov

7. Seizures. Epilepsy? is common with progressive cerebral atrophy and can worsen developmental regression. rarediseases.info.nih.gov

8. Visual impairment. Poor tracking, cortical visual impairment, or retinal involvement (in some storage disorders) are frequent. rarediseases.info.nih.gov

9. Weakness and fatigue?. Generalized? weakness appears as motor function fades and feeding becomes harder. disorders.eyes.arizona.edu

10. Swallowing problems and aspiration. Incoordination of swallowing raises pneumonia? risk and often requires feeding therapy or tube support. NCBI

11. Poor growth and weight gain. Energy needs increase while feeding declines, producing failure to thrive? without support. disorders.eyes.arizona.edu

12. Sleep disturbance. Disrupted sleep often accompanies neurodegeneration and seizure? disorders. rarediseases.info.nih.gov

13. Communication decline. Words and social interaction fade with cortical dysfunction and seizures. rarediseases.info.nih.gov

14. Frequent infections (secondary). Aspiration and immobility raise infection risk, though immunity? itself may be normal. NCBI

15. Breathing difficulties (advanced). Progressive neuromuscular weakness can impair cough?/respiration and require respiratory support. NCBI

Diagnostic tests

Clinicians combine clinical exam, targeted bedside tests, laboratory/pathology, electrodiagnostics, and imaging to confirm the pattern and identify the exact gene. The goal is both to recognize progressive cerebral atrophy and to pin down the cause (many are potentially testable for specific treatments or trials).

A) Physical examination

1. Growth and head-circumference tracking. Repeated head measurements show acquired microcephaly; weight/length often lag as feeding declines. This confirms progression?, a key clue in genetic neurodegeneration. rarediseases.info.nih.gov

2. Neurologic tone and reflexes. Mixed tone (axial hypotonia with limb hypertonia), scissoring, brisk reflexes, and pathologic reflexes reflect corticospinal tract involvement. rarediseases.info.nih.gov

3. Developmental milestone charting. Standardized developmental surveillance? documents loss of previously achieved skills, distinguishing degenerative from static encephalopathies. rarediseases.info.nih.gov

4. Vision and eye movements. Poor fixation/tracking or retinal signs point toward disorders like NCL; supranuclear gaze issues may coexist. Frontiers

5. Nutrition/respiratory status. Signs of feeding failure, aspiration risk, and weak cough guide urgency for swallow studies and support. NCBI

B) Manual/bedside tests

6. Bedside dysphagia screening. Careful observation during feeds checks for choking, coughing, wet voice, or prolonged feeding—signs that prompt instrumental studies. NCBI

7. Vision screening and visual behavior tools. Simple charts, light tracking, and contrast tests flag cortical visual impairment common in progressive encephalopathies. Frontiers

8. Tone and spasticity scales (e.g., Modified Ashworth). Structured scoring makes change over time clearer and helps tailor therapy plans. jnnp.bmj.com

9. Gross motor function measures. Serial scoring captures decline/regression and informs therapy and equipment needs. jnnp.bmj.com

10. Seizure diary and bedside seizure recognition. Families and clinicians document events to guide EEG and anti-seizure therapy. Seizure Journal

C) Laboratory & pathological tests

11. First-line metabolic screen. Blood/urine tests (ammonia, lactate, amino/organic acids, acylcarnitines) look for treatable inborn errors that can mimic ARCA. National Organization for Rare Disorders

12. Lysosomal enzyme panels / storage screening. Enzyme assays and biomarkers can reveal NCLs and other storage disorders that cause cerebral atrophy. Frontiers

13. Peroxisomal and mitochondrial panels. Very-long-chain fatty acids and mitochondrial markers (plus mtDNA/nuclear gene testing) help narrow etiologies. National Organization for Rare Disorders

14. Genetic testing (NGS panels, exome, genome). Modern sequencing finds many causes, although some remain unsolved; matching phenotype with gene directs care and counseling. jnnp.bmj.com

15. Targeted gene confirmation. When MRI/EEG patterns suggest a disorder (e.g., specific NCL subtype, TUBB4A spectrum), single-gene or focused panels can confirm rapidly. ajnr.org+1

16. Skin/other tissue pathology (selected cases). Storage material, abnormal inclusions, or electron microscopy findings can support diagnoses like NCL when genetics is inconclusive. Frontiers

D) Electrodiagnostic tests

17. Electroencephalogram (EEG). Frequent in ARCA work-ups because epilepsy is common; patterns such as generalized periodic discharges and diffuse slowing support genetic encephalopathy. PubMed Central

18. Evoked potentials (visual, brainstem). Abnormalities support central pathway dysfunction in disorders with visual loss or brainstem involvement. Frontiers

19. Polysomnography (sleep study) when needed. Seizures and breathing abnormalities can disrupt sleep; study results guide respiratory and seizure management. Seizure Journal

20. EMG/NCS (selected phenotypes). If peripheral motor neuron or neuropathic features are suspected (as in some RNA-processing disorders), nerve/muscle testing adds clarity. NCBI

E) Imaging tests

1. Brain MRI with volumetry is the single most informative test: it shows symmetrical cortical and white-matter atrophy with ventriculomegaly and helps distinguish leukodystrophies, hypomyelination, or storage patterns; serial MRIs document progression. Additional techniques (DTI for white-matter tract integrity and MR spectroscopy for metabolic patterns) refine the differential and guide which genetic panels to order. rarediseases.info.nih.gov+2NCBI+2

Non-pharmacological treatments (therapies & others)

In ARCA, rehabilitation, nutrition, and safety are the backbone of care. Below are 10 core, evidence-based measures written fully; clinicians typically combine many of these. (I can expand with 10 more program-level options—school supports, caregiver training modules, home positioning systems, adaptive tech, respite planning, etc.—on request.)

1. Physiotherapy & occupational therapy (goal-directed): Build daily skills (transfers, sitting balance, stretching to prevent contractures), optimize positioning, and reduce caregiver burden. Programs are individualized and re-set every few months. NICE

2. Early intervention services (birth–3 years): Earlier, family-centered programs improve cognitive, communication, and motor outcomes; referral should not wait for a final gene result. PubMed Central

3. Speech-language therapy & safe-swallow strategies: Thickened feeds, pacing, posture, and instrumented swallow when needed help prevent aspiration and support growth. PubMed

4. Nutrition optimization & gastrostomy when indicated: Registered dietitians set calories/protein and micronutrients; PEG is appropriate when oral intake is unsafe or insufficient. espghan.info+1

5. Hip surveillance & orthoses: Regular X-rays and use of ankle-foot orthoses for sitting/standing alignment in children with significant limitations. NICE

6. Spasticity & dystonia rehab (before meds): Seating, splints, task-practice, and comfort-sleep routines are first-line; they remain essential alongside medications. aacpdm.org+1

7. Respiratory hygiene & aspiration prevention: Airway clearance techniques, positioning, reflux management, and vaccination decrease infection burden. PubMed

8. Bone health promotion: Weight-bearing programs, sunlight exposure, and adequate calcium/vitamin D decrease fracture risk in non-ambulant children. aacpdm.org+1

9. Seizure action plan & rescue training at home/school: Written plans, triggers, and caregiver training improve safety and reduce emergency visits. FDA Access Data

10. Family support & coordinated rehab (“Rehabilitation 2030” vision): Multidisciplinary, longitudinal care improves participation and quality of life. World Health Organization+1

Drug treatments

There is no universal disease-modifying drug for “ARCA” as a group. Drugs below are evidence-based for symptoms (seizures, spasticity, dystonia, drooling, sleep). Always individualize doses; labels include warnings/contraindications.

Antiseizure medicines (examples):

1. Levetiracetam—broad-spectrum, IV/oral options; check mood/behavior. FDA Access Data+1

2. Valproate/divalproex—effective for many generalized seizures; monitor liver, platelets; avoid in certain metabolic defects and pregnancy. FDA Access Data+1

3. Lamotrigine—use slow titration (serious rash risk); useful in generalized and focal epilepsy. FDA Access Data

4. Topiramate—broad utility; monitor for decreased sweating, acidosis, cognitive slowing. FDA Access Data+1

5. Clobazam (adjunct for refractory seizures; benzodiazepine risks: sedation, dependence). FDA Access Data

6. Diazepam rescue (rectal gel for clusters/prolonged seizures at home). FDA Access Data+1

7. Midazolam nasal (NAYZILAM)—on-label for seizure clusters ≥12 y; strict frequency limits. FDA Access Data

Tone/spasticity/dystonia management:

1. Oral baclofen—first-line for spasticity; taper slowly to avoid withdrawal. FDA Access Data
2. Intrathecal baclofen (LIORESAL IT / GABLOFEN pumps)—for severe spasticity not controlled orally (requires screening test and implanted pump). FDA Access Data+1
3. Botulinum toxin type A injections—focal spasticity/dystonia management to ease care and improve posture. FDA Access Data

Drooling & comfort:

1. Glycopyrrolate solution (for sialorrhea)—reduces drooling; watch constipation/urinary retention. (FDA-labeled pediatric sialorrhea products are available; clinicians select brand/formulation per label.) NICE

Notes on safety and tailoring:

• Many children with ARCA have mitochondrial or metabolic vulnerabilities—valproate can be harmful in some (e.g., POLG-related) and may require L-carnitine rescue if toxicity occurs; use genetics/metabolics input. PubMed+1

• Rescue benzodiazepines (diazepam, midazolam) are powerful and must be used exactly as labeled. FDA Access Data

Dietary molecular supplements (when and why)

Supplements are adjuncts; evidence ranges from moderate (vitamin D in non-ambulant kids) to limited/conditional (CoQ10 outside genetic deficiency). Always dietitian + clinician-led.

1. Vitamin D—bone strength in non-ambulant children; typical diets/tube feeds may still be low; dosing individualized (many centers use 600–1000 IU/day; check 25-OH D). PubMed Central+1

2. Calcium (dietary or supplement)—with vitamin D to reduce fracture risk when weight-bearing is limited. aacpdm.org

3. L-Carnitine—consider only in valproate-treated patients at risk of carnitine depletion or with toxicity; routine prophylaxis remains debated. PubMed Central+1

4. Coenzyme Q10—only clearly indicated when there is a proven primary CoQ10 biosynthesis defect; generalized benefit otherwise is uncertain. PubMed Central+1

5. Whey-based or hydrolyzed formulas for delayed gastric emptying and retching in severe neurologic impairment. espghan.info

6. Fiber supplementation for constipation in low-mobility children (with hydration and medical oversight). PubMed

7. Omega-3 fatty acids for general cardiometabolic support; neurological disease-specific effects remain uncertain—use as nutrition support, not therapy. PubMed

8. Iron, B12, folate—correct documented deficiencies that worsen fatigue or cognition. PubMed

9. Electrolyte/trace element repletion with long-term tube feeding per dietitian plan. espghan.info

10. Calorie-dense modulars (fats/carbs/protein) for catch-up growth under dietetic supervision. espghan.info

Immunity-booster / regenerative / stem-cell–type” drugs

Important caution: There are no FDA-approved “immunity booster” or stem-cell drugs to reverse ARCA. What is used are devices or delivery systems that help symptoms (e.g., baclofen pumps) or neuromodulation for epilepsy. Below are regulated, label-based interventions sometimes labeled “advanced”:

1. Intrathecal baclofen pump (baclofen injection, LIORESAL IT / GABLOFEN): Surgical implant delivering tiny baclofen doses for severe spasticity. FDA Access Data+1

2. Vagus nerve stimulation (VNS) device for drug-resistant epilepsy; FDA-approved PMA device; reduces seizure frequency as adjunct. FDA Access Data+1

3. Botulinum toxin A—locally “regenerative” for function via tone reduction (not neural regeneration). FDA Access Data

4. (Research context) CoQ10 pathway rescue in proven CoQ10 biosynthesis defects—experimental case reports exist, not standard care. Live Science

5. Ketogenic diet (not a “drug,” but a metabolic therapy) in refractory epilepsy—requires specialist monitoring; evidence long-standing. (Use local protocol/guidelines.) PubMed

6. Bisphosphonates for severe osteoporosis in CP (careful pediatric oversight; long-term safety on growth still studied). aacpdm.org

Surgeries / procedures (what they do and why)

1. Percutaneous Endoscopic Gastrostomy (PEG): Places a feeding tube into stomach to ensure safe, adequate nutrition when swallowing is unsafe or oral intake is insufficient/too slow. Improves growth, reduces aspiration risk. espghan.org

2. Selective Dorsal Rhizotomy (SDR): Neurosurgeon cuts selected sensory rootlets in lower spine to reduce spasticity and improve gait in carefully chosen ambulant children (GMFCS II–III). Irreversible; risks and long-term outcomes must be discussed. NCBI+1

3. Intrathecal Baclofen Pump Implantation: For severe generalized spasticity unresponsive to oral meds; allows dose titration with fewer systemic effects. FDA Access Data

4. Vagus Nerve Stimulator placement: Adjunctive therapy for medication-resistant epilepsy to lower seizure burden. FDA Access Data+1

5. Orthopedic surgeries (hip reconstruction, scoliosis correction) when surveillance shows progressive deformity or pain/skin risk. NICE

Preventions (risk-reduction steps families can take with the team)

1. Early genetic diagnosis to avoid harmful drugs (e.g., valproate in certain mitochondrial disorders) and to access trials. PubMed

2. Vaccinations and aspiration prevention to reduce pneumonia. PubMed

3. Seizure action plans and rescue med training at home/school. FDA Access Data

4. Nutrition optimization (dietitian-led; timely PEG). espghan.info

5. Bone health (vitamin D/calcium, weight bearing). aacpdm.org

6. Hip/spine surveillance to catch problems before they cause pain. NICE

7. Positioning and pressure care to prevent contractures/sores. aacpdm.org

8. Sleep and airway assessment if snoring, pauses, or daytime fatigue. aacpdm.org

9. Infection control and reflux management to reduce chest events. PubMed

10. Care coordination under a multidisciplinary rehab model. World Health Organization

When to see a doctor

• Any first seizure, seizure lasting >5 minutes, or repeated clusters without recovery. FDA Access Data

• Choking, coughing with feeds, weight loss, dehydration, or recurrent chest infections—likely needs swallow study or PEG. espghan.org

• Rapid regression (loss of skills), new weakness or severe stiffness/dystonia interfering with care. aacpdm.org

• Persistent pain, hip asymmetry, or curving spine—needs orthopedic/rehab review. NICE

• Fragility fracture or very low vitamin D—bone health work-up. aacpdm.org

What to eat and what to avoid

Eat/aim for: balanced calories; adequate protein for growth and muscle maintenance; calcium + vitamin D sources (or supplements); fiber and fluids to prevent constipation; specialized formulas (including whey-based) if gastric emptying is poor. Dietitians fine-tune plans and can add modular calories for catch-up growth. espghan.info+1

Avoid/caution: unsafe textures if swallow is impaired; excessive sedatives without a plan; unproven “stem-cell” or “immune booster” products marketed for neurodegeneration; and valproate in certain mitochondrial disorders where it is contraindicated—this is why genetic input matters. espghan.org+1

FAQs

1. Is “ARCA” one disease? No—it’s a description. Dozens of rare autosomal-recessive conditions cause cerebral atrophy. The goal is to name the gene. PubMed

2. Why does MRI show atrophy? Neurons and their connections are lost or under-developed, so fluid spaces enlarge. MRI patterns help narrow the cause. PubMed Central

3. What single best test should we do? In most children with early-onset DD/ID or anomalies, exome/genome sequencing now has the highest yield. PubMed

4. Will medicines reverse the atrophy? Current drugs mainly control symptoms (seizures, tone, drooling). Disease-specific cures are rare and depend on the exact gene. ajnr.org

5. Are there any device options? Yes—VNS for refractory epilepsy; intrathecal baclofen pumps for severe spasticity; botulinum toxin for focal tone. FDA Access Data+2FDA Access Data+2

6. Do we need a feeding tube? If swallowing is unsafe or intake is inadequate, PEG can improve nutrition and reduce aspiration. espghan.org

7. Do supplements help? Vitamin D/calcium for bone health are standard in non-ambulant kids; other supplements (e.g., CoQ10) are only for proven deficiencies. aacpdm.org+1

8. Is SDR right for my child? Only for selected ambulant children with spastic CP-like patterns; risks/benefits must be weighed carefully. NICE

9. Why avoid valproate sometimes? In some mitochondrial/genetic conditions it can worsen liver/brain injury—genetics guides antiseizure choices. PubMed

10. How often should hips/spine be checked? Follow hip surveillance protocols with periodic X-rays in children at risk. NICE

11. What about bone density? Consider DXA if fractures or risk factors; manage with nutrition, weight-bearing, and sometimes bisphosphonates. pghn.org+1

12. Are there clinical trials? Trials are gene-specific; once the gene is known, search registries and rare-disease networks. (General guidance.) acmg.net

13. Can early therapy change outcomes? Yes—early intervention improves developmental trajectories. PubMed Central

14. What if seizures cluster at home? Use a written rescue plan with on-label nasal midazolam or rectal diazepam per age/label limits. FDA Access Data+1

15. What’s the long-term outlook? Highly variable by gene; some conditions are slowly progressive, others faster. Accurate genetic diagnosis anchors prognosis. PubMed

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 06, 2025.